Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Denton

Showing results (261-270 of 607) with videos related to

Pageof 61
Sort By:
Gut|September 10, 2005
Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosisC Rigamonti, L M Shand, M Feudjo, et al.
The Journal of Rheumatology|April 3, 2008
Single-nucleotide polymorphisms in CCL2 gene are not associated with susceptibility to systemic sclerosisMaria Teresa Carulli, Paolo Spagnolo, Carmen Fonseca, et al.
Clinical and Experimental Rheumatology|April 6, 2021
Autologous lipotransfer can improve the outcomes of localised sclerodermaBenjamin J Langridge, Faith H K Jeon, Aurora Almadori, et al.
Annals of the Rheumatic Diseases|September 23, 2020
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosisYannick Allanore, Peter Wung, Christina Soubrane, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2018
Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension StudyYannick Allanore, Oliver Distler, Alexandre Jagerschmidt, et al.
Rheumatology (Oxford, England)|October 3, 2008
Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layerN Aden, X Shiwen, D Aden, et al.
Clinical and Experimental Rheumatology|May 18, 2004
Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic reviewM Dziadzio, R E Smith, D J Abraham, et al.
Annals of the Rheumatic Diseases|February 7, 2002
Non-invasive measurement of biomechanical skin properties in systemic sclerosisA Balbir-Gurman, C P Denton, B Nichols, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 22, 2020
Prospective evaluation of treatment response and disease reversibility of paediatric localized scleroderma (morphoea) to steroids and methotrexate using multi-modal imagingL Weibel, M Theiler, K J Howell, et al.
Scientific Reports|July 2, 2022
Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypesKristina E N Clark, Corrado Campochiaro, Lauren V Host, et al.
Pageof 61

Showing results (261-270 of 607) with videos related to

Sort By:
Pageof 61
Gut|September 10, 2005
Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosisC Rigamonti, L M Shand, M Feudjo, et al.
The Journal of Rheumatology|April 3, 2008
Single-nucleotide polymorphisms in CCL2 gene are not associated with susceptibility to systemic sclerosisMaria Teresa Carulli, Paolo Spagnolo, Carmen Fonseca, et al.
Clinical and Experimental Rheumatology|April 6, 2021
Autologous lipotransfer can improve the outcomes of localised sclerodermaBenjamin J Langridge, Faith H K Jeon, Aurora Almadori, et al.
Annals of the Rheumatic Diseases|September 23, 2020
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosisYannick Allanore, Peter Wung, Christina Soubrane, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2018
Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension StudyYannick Allanore, Oliver Distler, Alexandre Jagerschmidt, et al.
Rheumatology (Oxford, England)|October 3, 2008
Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layerN Aden, X Shiwen, D Aden, et al.
Clinical and Experimental Rheumatology|May 18, 2004
Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic reviewM Dziadzio, R E Smith, D J Abraham, et al.
Annals of the Rheumatic Diseases|February 7, 2002
Non-invasive measurement of biomechanical skin properties in systemic sclerosisA Balbir-Gurman, C P Denton, B Nichols, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 22, 2020
Prospective evaluation of treatment response and disease reversibility of paediatric localized scleroderma (morphoea) to steroids and methotrexate using multi-modal imagingL Weibel, M Theiler, K J Howell, et al.
Scientific Reports|July 2, 2022
Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypesKristina E N Clark, Corrado Campochiaro, Lauren V Host, et al.
Pageof 61